Skip to main content

Syneos Health Acquires RxDataScience

Written by Customer Service on . Posted in Mergers And Acquisitions.

Acquisition Delivers AI and Data Engineering Expertise, Enterprise Analytics and Technology-Enabled Solutions to Accelerate Customer Performance

MORRISVILLE, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the acquisition of RxDataScience, a leading healthcare-focused data analytics, data management and artificial intelligence (AI) company. Together, Syneos Health and RxDataScience will offer biopharma customers technology-enabled, insights-powered solutions with the aim of accelerating performance across the product lifecycle – from lab to life.

RxDataScience’s scalable platform enables biopharma companies to transform vast volumes of data into strategic, actionable insights. Multidisciplinary teams of product managers, data scientists, engineers, developers and domain experts leveraging insights drawn from providers, payers and patients contribute to RxDataScience’s innovative software solutions, helping to deliver radical improvements that can enhance patients’ lives.  

The acquisition brings advanced solutions that go beyond basic reporting to sophisticated Augmented Intelligent Insights and Biopharma Analytics platforms. RxDataScience’s product lifecycle solutions include scientific computing for R&D, patient journey, decentralized trials, RWE, predictive analytics and commercial market research. Additionally, RxDataScience offers an accelerated consulting-based model, providing an iterative approach to rapidly develop and deliver advanced analytics solution prototypes in six-to-eight-week sprints.

“This acquisition boosts our ability to deliver strategic insights and technology-enabled solutions that address our customers’ most complex data challenges,” said Alistair Macdonald, CEO, Syneos Health. “We are thrilled to welcome the RxDataScience team to the Syneos Health family. Combining our end-to-end services and deep behavioral and therapeutic expertise with their AI and data-science capabilities will generate customer strategies to accelerate product development and time to market.”

RxDataScience further scales Syneos Health’s data science abilities, adding new capabilities and deep knowledge in data engineering and management, and advanced enterprise analytics that accelerate the time to commercialization for products and customer performance, with the potential to significantly shorten clinical trials and modernize medical affairs and commercial programs.  

RxDataScience is complementary to Kinetic™, Syneos Health’s modern customer engagement capability built to address business-critical challenges with greater precision, efficiency and effectiveness by combining behavioral science, analytics and the latest technologies to deliver fully integrated omnichannel solutions.

“RxDataScience has dedicated its first five years to building a vision, talent and technology that address challenges in data management, data science and AI faced by biopharma companies,” said Sayee Natarajan, CEO and Co-Founder, RxDataScience. “We’re excited to join Syneos Health, giving us a tremendous opportunity to scale our services, expand our market and offer solutions to a larger customer base. We’re particularly excited to be part of an ecosystem built on innovation and an entrepreneurial approach for delivering novel solutions and new capabilities to customers.”

RxDataScience will be part of the Syneos Health Dynamic Assembly® network, an open ecosystem of best-of-breed data and technology collaborators designed to strategically address the nuances of unique customer engagements, providing an “always on” innovation environment.

About RxDataScience
RxDataScience builds AI and advanced analytics solutions to address and answer the challenges with healthcare information management and analysis. Their vision is to create a large suite of apps solving specific business problems across the entire pharmaceutical and healthcare value chain. These apps contain advanced analytics and link large data sets enabling business analysts and non-programmers to extract business value from disparate healthcare data sources.

About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 27,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Investor Relations Contact:
Ronnie Speight
Senior Vice President, Investor Relations
+1 919 745 2745
Investor.Relations@syneoshealth.com 		Press/Media Contact:
Gary Gatyas
Executive Director, External Communications
+1 908 763 3428
gary.gatyas@syneoshealth.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.